HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Peter Libby Selected Research

Thromboplastin (Tissue Factor)

1/2021Resilience of the Internal Mammary Artery to Atherogenesis: Shifting From Risk to Resistance to Address Unmet Needs.
11/2019Interleukin-1β Mediates Arterial Thrombus Formation via NET-Associated Tissue Factor.
11/2016Inflammation and thrombosis - testing the hypothesis with anti-inflammatory drug trials.
1/2016Mechanisms of Myeloid Cell Modulation of Atherosclerosis.
1/2015Statins improve the resolution of established murine venous thrombosis: reductions in thrombus burden and vein wall scarring.
2/2013Adiponectin inhibits macrophage tissue factor, a key trigger of thrombosis in disrupted atherosclerotic plaques.
2/2010Inflammation in atherosclerosis: transition from theory to practice.
1/2007Intertwining of thrombosis and inflammation in atherosclerosis.
1/2003Effects of statins in reducing thrombotic risk and modulating plaque vulnerability.
9/2002Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Peter Libby Research Topics

Disease

167Atherosclerosis
03/2024 - 01/2002
127Inflammation (Inflammations)
03/2024 - 01/2002
77Atherosclerotic Plaque (Atheroma)
03/2024 - 01/2002
63Myocardial Infarction
05/2024 - 02/2002
61Cardiovascular Diseases (Cardiovascular Disease)
03/2024 - 09/2002
48Thrombosis (Thrombus)
05/2024 - 05/2002
29Coronary Artery Disease (Coronary Atherosclerosis)
04/2024 - 12/2002
23Stroke (Strokes)
04/2024 - 05/2002
23Acute Coronary Syndrome
01/2023 - 09/2003
21Abdominal Aortic Aneurysm
01/2023 - 11/2004
15Rupture
01/2023 - 10/2002
13Obesity
09/2023 - 03/2006
13Coronary Disease (Coronary Heart Disease)
01/2023 - 07/2004
12Unstable Angina
10/2023 - 09/2003
11Infections
09/2023 - 01/2002
11COVID-19
09/2023 - 01/2020
10Infarction (Infarctions)
01/2023 - 02/2002
10Hypertension (High Blood Pressure)
09/2022 - 05/2002
10Neoplasms (Cancer)
06/2022 - 11/2008
9Heart Failure
11/2023 - 04/2014
9Rheumatoid Arthritis
09/2022 - 04/2009
9Fibrosis (Cirrhosis)
01/2022 - 03/2007
8Type 2 Diabetes Mellitus (MODY)
11/2022 - 06/2003
8Metabolic Syndrome (Dysmetabolic Syndrome X)
01/2019 - 02/2006
7Insulin Resistance
09/2023 - 03/2004
7Chronic Renal Insufficiency
01/2023 - 04/2009
7Aneurysm (Aneurysms)
01/2022 - 05/2005
7Dyslipidemias (Dyslipidemia)
10/2021 - 11/2004
7Disease Progression
01/2018 - 04/2006
6Atrial Fibrillation
02/2024 - 07/2011
6Myocardial Ischemia (Ischemic Heart Diseases)
01/2023 - 09/2003
6Osteoarthritis
09/2022 - 04/2009
6Vascular Diseases (Vascular Disease)
11/2020 - 12/2002
6Diabetes Mellitus
01/2020 - 05/2002
5Pathologic Constriction (Stenosis)
01/2023 - 01/2003
5Hypoxia (Hypoxemia)
10/2022 - 08/2011
5Arthritis (Polyarthritis)
09/2022 - 09/2002
5Calcinosis
01/2020 - 06/2013
4Gout
03/2024 - 10/2018
4Necrosis
10/2023 - 11/2021

Drug/Important Bio-Agent (IBA)

62LipidsIBA
01/2024 - 01/2002
54CytokinesIBA
12/2023 - 01/2002
50Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
11/2023 - 09/2002
43CholesterolIBA
04/2024 - 05/2002
35C-Reactive ProteinIBA
11/2023 - 03/2002
33Biomarkers (Surrogate Marker)IBA
01/2024 - 10/2005
27Apolipoproteins E (ApoE)IBA
10/2022 - 02/2005
26Proteins (Proteins, Gene)FDA Link
04/2024 - 09/2002
24Interleukin-6 (Interleukin 6)IBA
09/2023 - 09/2003
23oxidized low density lipoproteinIBA
01/2024 - 09/2002
21LDL CholesterolIBA
01/2023 - 06/2003
20canakinumabFDA Link
12/2023 - 10/2011
20CollagenIBA
01/2023 - 02/2002
20Atorvastatin (Lipitor)FDA Link
01/2020 - 09/2003
18Rosuvastatin Calcium (Crestor)FDA Link
08/2017 - 03/2004
16Matrix Metalloproteinases (MMPs)IBA
11/2022 - 01/2002
16Lipoproteins (Lipoprotein)IBA
01/2022 - 08/2002
15InterleukinsIBA
01/2022 - 01/2002
15Peptide Hydrolases (Proteases)FDA Link
01/2019 - 03/2003
15CD40 Ligand (CD40L)IBA
11/2011 - 12/2002
14InflammasomesIBA
02/2024 - 10/2014
14HDL CholesterolIBA
11/2022 - 06/2003
14ApolipoproteinsIBA
05/2016 - 02/2005
12ChemokinesIBA
10/2023 - 01/2002
12Triglycerides (Triacylglycerol)IBA
11/2022 - 06/2003
11Glucose (Dextrose)FDA LinkGeneric
01/2024 - 08/2007
11EnzymesIBA
11/2023 - 07/2004
11Angiotensin IIIBA
01/2022 - 03/2009
11Thromboplastin (Tissue Factor)IBA
01/2021 - 07/2002
11LDL Receptors (LDL Receptor)IBA
11/2020 - 01/2002
10Monoclonal AntibodiesIBA
12/2023 - 12/2012
10Cysteine Proteases (Cysteine Protease)IBA
01/2018 - 08/2004
9Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA
01/2023 - 11/2012
9Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
10/2022 - 10/2002
9LDL Lipoproteins (beta Lipoproteins)IBA
01/2022 - 11/2004
9Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA
04/2015 - 09/2002
8omega-Chloroacetophenone (Mace)IBA
12/2023 - 11/2013
8Interleukin-18 (Interleukin 18)IBA
12/2022 - 01/2002
8ElastinIBA
05/2016 - 04/2003
8AdiponectinIBA
02/2013 - 03/2006
7InterferonsIBA
11/2023 - 01/2002
7Naproxen (Naprosyn)FDA LinkGeneric
09/2022 - 04/2009
7Celecoxib (Celebrex)FDA Link
09/2022 - 04/2009
7Ibuprofen (Motrin)FDA LinkGeneric
09/2022 - 04/2009
7Immunoglobulin E (IgE)IBA
01/2020 - 09/2011
7CathepsinsIBA
09/2019 - 04/2007
7Collagenases (Collagenase)FDA Link
06/2014 - 02/2002
6Messenger RNA (mRNA)IBA
06/2015 - 05/2006
5Apolipoprotein A-I (Apolipoprotein A1)IBA
04/2024 - 07/2010
5Insulin (Novolin)FDA Link
12/2022 - 05/2002
5Cathepsin LIBA
01/2020 - 02/2006
5Cathepsin KIBA
01/2019 - 05/2007
5CalciumIBA
01/2018 - 09/2007
5cathepsin SIBA
04/2015 - 03/2003
5Interferon-gamma (Interferon, gamma)IBA
08/2009 - 05/2005
4HDL LipoproteinsIBA
04/2024 - 11/2014
4Complement System Proteins (Complement)IBA
12/2023 - 08/2002

Therapy/Procedure

83Therapeutics
05/2024 - 01/2002
6Secondary Prevention
03/2024 - 05/2007
5Stents
03/2024 - 06/2011